Survival of Resectable Stage II Colon Cancer Patients: Focus on Chemotherapy-Experience from a Single Institution

BackgroundAdjuvant chemotherapy for stage II resectable colon cancer has not been found to impact outcome. Most of the benefit of adjuvant therapy was seen in high-risk stage II disease. We analyzed the survival data from the cancer registry database of our institution to determine the efficacy of adjuvant chemotherapy in stage II colon cancer patients.Materials and MethodsFrom 2007 to 2012, 176 patients with resectable stage II colon cancer were treated at CGH. Overall survival (OS) analysis and sub-group analysis were performed.ResultsMean follow-up was 40.37 months. Survival of stage II colon cancer was superior in patients receiving adjuvant chemotherapy than in those without chemotherapy (p=0.003). Three-year OS was 82% vs. 61% (p=0.004). Survival was better in patients with left side colon cancer receiving chemotherapy (HR 0.093, p=0.002) and in male patients receiving chemotherapy (HR 0.216, p=0.010).ConclusionsBased on our study results, we recommend adjuvant chemotherapy in patients with stage II left side colon cancer in addition to in patients with high risk stage II colon cancer.